These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127 [TBL] [Abstract][Full Text] [Related]
4. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874 [TBL] [Abstract][Full Text] [Related]
5. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials. Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132 [TBL] [Abstract][Full Text] [Related]
6. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia. Mokhtar GM; Tantawy AA; El Sherif NH Platelets; 2012; 23(4):264-73. PubMed ID: 22471399 [TBL] [Abstract][Full Text] [Related]
7. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. Chouhan JD; Herrington JD Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632 [TBL] [Abstract][Full Text] [Related]
8. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Klaassen RJ; Mathias SD; Buchanan G; Bussel J; Deuson R; Young NL; Collier A; Bomgaars L; Blanchette V Pediatr Blood Cancer; 2012 Mar; 58(3):395-8. PubMed ID: 21910213 [TBL] [Abstract][Full Text] [Related]
9. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Iwato K; Okamoto S; Kurokawa M; Kirito K; Hashino S; Ninomiya H; Mori S; Yonemura Y; Usuki K; Wei H; Lizambri R Int J Hematol; 2012 Jun; 95(6):652-9. PubMed ID: 22532046 [TBL] [Abstract][Full Text] [Related]
10. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital. Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim. Meletis J; Katsandris A; Raptis SD; Mantzourani M Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616 [TBL] [Abstract][Full Text] [Related]
12. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura. Newland A Eur J Haematol Suppl; 2009 Mar; (71):20-5. PubMed ID: 19200304 [TBL] [Abstract][Full Text] [Related]
13. Use of romiplostim for primary immune thrombocytopenia in children. Escudero Vilaplana V; Aragonés JH; Fernández-Llamazares CM; Bieler CB; Rodríguez SM; Sáez MS Pediatr Hematol Oncol; 2012 Mar; 29(2):197-205. PubMed ID: 22376020 [TBL] [Abstract][Full Text] [Related]
14. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Jamali F; Lemery S; Ayalew K; Robottom S; Robie-Suh K; Rieves D; Pazdur R Oncology (Williston Park); 2009 Jul; 23(8):704-9. PubMed ID: 19711585 [TBL] [Abstract][Full Text] [Related]
15. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience. Pasquet M; Aladjidi N; Guiton C; Courcoux MF; Munzer M; Auvrignon A; Lutz P; Ducassou S; Leroy G; Munzer C; Leverger G; Br J Haematol; 2014 Jan; 164(2):266-71. PubMed ID: 24152194 [TBL] [Abstract][Full Text] [Related]
16. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038 [TBL] [Abstract][Full Text] [Related]
17. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia. Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824 [TBL] [Abstract][Full Text] [Related]
18. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Okamoto S; Kurokawa M; Kirito K; Yonemura Y; Mori S; Usuki K; Iwato K; Hashino S; Wei H; Lizambri R Int J Hematol; 2011 Jul; 94(1):71-80. PubMed ID: 21706145 [TBL] [Abstract][Full Text] [Related]
19. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry. Doobaree IU; Newland A; McDonald V; Nandigam R; Mensah L; Leroy S; Seesaghur A; Patel H; Wetten S; Provan D Eur J Haematol; 2019 May; 102(5):416-423. PubMed ID: 30758874 [TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]